Spirobarbital

Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s.[1] It has hypnotic and sedative effects, and has a moderate potential for abuse.[2]

Spirobarbital
Clinical data
Other names5-spiro-(2'-ethyl-3'-5'-dimethyl-cyclopentyl)barbituric acid
ATC code
  • none
Identifiers
IUPAC name
  • 1-ethyl-2,4-dimethyl-7,9-diazaspiro[4.5]decane-6,8,10-trione
CAS Number
UNII
Chemical and physical data
FormulaC12H18N2O3
Molar mass238.287 g·mol−1
3D model (JSmol)
SMILES
  • O=C2NC(=O)NC(=O)C12C(CC)C(C)CC1C
  (verify)

References
  1. US 2561688, Doran WJ, Van Heyningen EM, "Spirobarbituric Acids", issued 24 July 1951, assigned to Eli Lilly and Company
  2. Isbell H, Chruściel TL (1970). "Dependence liability of "non-narcotic" drugs". Bulletin of the World Health Organization. 43 (Supplement): 5–104. PMID 20718122.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.